Cover Image
市場調查報告書

全球生技仿製藥市場上法規·開發平台分析

Global Biosimilars Market Regulations & Pipeline Insight

出版商 KuicK Research 商品編碼 311587
出版日期 內容資訊 英文 836 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生技仿製藥市場上法規·開發平台分析 Global Biosimilars Market Regulations & Pipeline Insight
出版日期: 2014年09月02日 內容資訊: 英文 836 Pages
簡介

本報告提供全球生技仿製藥市場相關調查,提供您市場概要,市場展望,市場課題,成長機會,法規情形,開發平台分析及競爭情形等分析。

第1章 全球生技仿製藥市場展望

  • 市場概要
  • 臨床實驗平台分析

第2章 全球生技仿製藥市場動態

  • 有利的市場指標
  • 應討論的課題

第3章 全球生技仿製藥市場上未來的成長機會

第4章 生技仿製藥的開發·行銷法規途徑

  • 澳洲
  • 加拿大
  • 歐洲
  • 日本
  • 印度
  • 馬來西亞
  • 沙烏地阿拉伯
  • 新加坡
  • 南非
  • 韓國
  • 土耳其
  • 美國

第5章 全球生技仿製藥開發平台:階段·適應症·企業·各國

  • 確認階段
  • 研究
  • 前臨床
  • 臨床
  • 階段-0
  • 階段-I
  • 階段-I/II
  • 階段-II
  • 階段-III
  • 預註冊
  • 已經過核准

第6章 已上市的生技仿製藥:適應症·企業·各國

第7章 停止·中止的生技仿製藥開發平台:階段·適應症·企業·各國

  • 未開發
  • 停止
  • 中止

第8章 競爭情形

  • Actavis
  • Amgen
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Biocon
  • Bio Sidus
  • Dong-A Pharmaceutical
  • Harvest Moon Pharmaceuticals
  • Inbiopro Solutions
  • Mylan
  • Reliance Life Sciences
  • Sandoz International
目錄

The evolution of biosimilars has currently reached different stages across the world. Owing to variable clarity in the guidelines and diverse regulatory pathways, various definitions of biosimilars (or the broader group of follow-on biologics) have emerged across countries. Till now the European region has the best-established framework for biosimilars. The US is currently almost aligned to the European standards. Biosimilars are also known as follow on biologics in the US and subsequent entry biologics in Canada, are biologic products which are approved in a country, which has an abbreviated approval process for biologic products which references an originator biologic in the regulatory submission.

The global biosimilars market is categorized into monoclonal antibody biosimilars (mAbs), insulins, interferons, erythropoetins, filgrastim, somatropin and follicle stimulating hormone (FSH). Among the segments of the biosimilars market, the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share of more than 40% of the total global biosimilars market by 2018. Additionally, with the mAbs having one of the strongest R&D pipeline in the biologics market, it is expected that many new next-generation technologies which would push mAb therapeutics into newer areas such as solid tumours, cardiovascular and neurological disorders would be introduced into the market.

In terms of innovation in the biosimilars, it is most likely that the future market would witness the introduction of follitropins, interferons and low molecular weight heparins products, in addition to mAbs. Also, it is expected that some pharmaceutical companies could increasingly start focusing on specific therapeutic classes based on their capacity to manufacture and their strategic fit.

Almost all the countries across the globe are currently experiencing an increase in their ageing population with a parallel increase in the incidence of chronic diseases. However, an increase in the demand for high quality healthcare is generally associated with the issue of controlling spiraling healthcare expenditure. With the regulated and streamlined introduction of biosimilars into the market, it is most likely that there would be an increase in the accessibility and affordability of the much in demand biologic medicines. The next few years are likely to witness a new set of complex biosimilars products being developed owing to a significant number of leading brands of biologic drugs losing their patents by 2020.

“Global Biosimilars Market Regulations & Pipeline Insight” Report Highlights:

  • Market Overview
  • Detailed Regulatory Pathways For 12 Countries/Regions
  • Global Biosimilars Pipeline by Phase, Indication, Company & Country
  • Biosimilars Pipeline: 276 in Development Phase
  • Majority Biosimilars in Preclinical Phase: 76 Biosimilars
  • Marketed Biosimilars by Indication, Company & Country: 113 Biosimilars

Table of Contents

1. Global Biosimilars Market Outlook

  • 1.1. Market Overview
  • 1.2. Clinical Pipeline Insight

2. Global Biosimilars Market Dynamics

  • 2.1. Favorable Market Parameters
  • 2.2. Issues to be Discussed

3. Global Biosimilars Market Future Growth Opportunities

4. Regulatory Pathways for Development & Marketing of Biosimilars

  • 4.1. Australia
  • 4.2. Canada
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. India
  • 4.6. Malaysia
  • 4.7. Saudi Arabia
  • 4.8. Singapore
  • 4.9. South Africa
  • 4.10. South Korea
  • 4.11. Turkey
  • 4.12. US

5. Global Biosimilars Pipeline by Phase, Indication, Company & Country

  • 5.1. Unknown
  • 5.2. Research
  • 5.3. Preclinical
  • 5.4. Clinical
  • 5.5. Phase-0
  • 5.6. Phase-I
  • 5.7. Phase-I/II
  • 5.8. Phase-II
  • 5.9. Phase-III
  • 5.10. Preregistration
  • 5.11. Registered

6. Marketed Biosimilars by Indication, Company & Country

7. Suspended & Discontinued Biosimilars Pipeline by Phase, Indication, Company & Country

  • 7.1. No Development Reported
  • 7.2. Discontinued
  • 7.3. Suspended

8. Competitive Landscape

  • 8.1. Actavis
  • 8.2. Amgen
  • 8.3. BioXpress Therapeutics
  • 8.4. Boehringer Ingelheim
  • 8.5. Biocon
  • 8.6. Bio Sidus
  • 8.7. Dong-A Pharmaceutical
  • 8.8. Harvest Moon Pharmaceuticals
  • 8.9. Inbiopro Solutions
  • 8.10. Mylan
  • 8.11. Reliance Life Sciences
  • 8.12. Sandoz International
  • Figure 1-1: Global Biosimilars Market (US$ Billion), 2013-2018
  • Figure 1-2: Global Biosimilars Market by Segment (%), 2018
  • Figure 1-3: Global Biosimilars Clinical Pipeline by Phase (%), 2014
  • Figure 1-4: Global Biosimilars Clinical Pipeline by Phase (Number), 2014
  • Figure 1-5: No Development Reported in Biosimilars Clinical Pipeline by Phase (%), 2014
  • Figure 1-6: No Development Reported in Biosimilars Clinical Pipeline by Phase (Number), 2014
  • Figure 1-7: Discontinued Biosimilars in Clinical Pipeline by Phase (%), 2014
  • Figure 1-8: Discontinued Biosimilars in Clinical Pipeline by Phase (Number), 2014
  • Figure 7-1: Biocon Biosimilars Pipeline
  • Figure 7-2: Harvest Moon Pharmaceuticals Biosimilars Pipeline
Back to Top